Pressmeddelanden från Pharma Equity

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Pharma Equity Group’s subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant 28 apr 09:30

The Board of Directors' resolution on the issuance of convertible loans 17 apr 16:48

Proceedings of the Annual General Meeting of Pharma Equity Group A/S 25 mar 16:10

Notice convening the annual general meeting in Pharma Equity Group A/S 25 mar 12:51

Pharma Equity Group A/S - Annual Report 2025 18 mar 13:24

UPDATE OF THE FINANCIAL CALENDAR FOR 2026 26 feb 16:24

SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 2025 03 feb 08:00

2026 Financial Calendar 29 dec 2025 16:32

Pharma Equity Group – Strategic update and adjustment of expectations 10 dec 2025 12:17

Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S 03 dec 2025 08:19

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026 01 dec 2025 13:10

The Board of Directors' resolution on the issuance of convertible loans 26 nov 2025 16:40

Corrective information regarding the Annual Report 2024 and the Interim Report for H1 2025 following an order from the Danish Business Authority 01 okt 2025 09:24

The Board of Directors' resolution on the issuance of convertible loans 02 sep 2025 10:04

Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis 01 sep 2025 13:06

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis 14 aug 2025 09:07

Consolidated Interim Report 1 January – 30 June 2025 01 jul 2025 17:31

The Board of Directors' resolution on the issuance of convertible loans 28 maj 2025 10:29

Pharma Equity Group A/S Launches New Strategy to Drive Growth and Shareholder Returns 05 maj 2025 10:43

Passing of the General Meeting of Pharma Equity Group A/S 01 apr 2025 13:29

The Board of Directors' resolution on the issuance of convertible loans 25 mar 2025 11:00

Notice convening the annual general meeting in Pharma Equity Group A/S 20 mar 2025 08:04

Pharma Equity Group A/S - Annual Report 2024 28 feb 2025 13:19

2025 Financial Calendar 28 feb 2025 12:56

Change of executive management and organizational change in Pharma Equity Group A/S 14 jan 2025 10:06

Pharma Equity Group 2025 Financial Calendar 13 dec 2024 12:21

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.29 nov 2024 07:45

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S 15 nov 2024 08:33

Consolidated Interim report 1 January – 30 September 2024 23 okt 2024 10:28

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.14 okt 2024 08:17

Major shareholder announcement - Pharma Equity Group A/S 14 okt 2024 08:00

Managers’ transactions 11 okt 2024 08:37

Pharma Equity Group announces successful completion of directed issue of new shares 04 okt 2024 13:52

Pharma Equity Group announces issuance of new shares in a direct issue 04 okt 2024 09:01

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights 16 aug 2024 08:52

Consolidated Interim Report 1 January – 30 June 2024 16 jul 2024 10:09

The Board of Directors' decision to issue convertible loans 15 jul 2024 16:23

Major shareholder announcement - Pharma Equity Group A/S 15 jul 2024 16:13

Major shareholder announcement - Pharma Equity Group A/S 03 jun 2024 16:17

Results of extraordinary general meeting in Pharma Equity Group A/S 16 maj 2024 12:35

The Board of Director's decision to issue convertible loans 16 maj 2024 07:27

Consolidated interim report 1 January – 31 March 2024 08 maj 2024 15:17

Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S 08 maj 2024 10:20

Notice convening the extraordinary general meeting of Pharma Equity Group A/S 23 apr 2024 11:45

Major shareholder announcement - Pharma Equity Group A/S 16 apr 2024 17:29

Passing of the General Meeting of Pharma Equity Group A/S 10 apr 2024 14:21

The Board of Director's decision to issue convertible loans 05 apr 2024 11:22

Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.25 mar 2024 13:06

Notice convening the annual general meeting in Pharma Equity Group A/S 22 mar 2024 09:00

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009 21 mar 2024 16:33

Completion of subscription of convertible loans 20 mar 2024 17:15

Correction: Pharma Equity Group A/S - Annual Report 2023 20 mar 2024 08:58

Pharma Equity Group A/S - Annual Report 2023 05 mar 2024 10:11

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).07 feb 2024 13:38

Completion of subscription of convertible loans 07 feb 2024 09:46

The Board of Director's decision to issue convertible loans 25 jan 2024 10:08

Completion of subscription of convertible loans 22 jan 2024 16:15

Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).22 jan 2024 15:54

The Board of Director's decision to issue convertible loans 28 nov 2023 18:30

Status of the Company's receivable from Portinho S.A.28 nov 2023 14:56

2024 Financial Calendar 16 nov 2023 12:17

Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051.16 nov 2023 08:26

Consolidated interim report 1 January – 30 September 2023 02 nov 2023 15:14

Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S 31 okt 2023 13:18

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Intention to Grant” for patents of the subsidiary's wound-healing drug combination and the treatment of colorectal cancer.31 okt 2023 11:57

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing composition.11 okt 2023 12:27

Notice convening the extraordinary general meeting of Pharma Equity Group A/S 25 sep 2023 20:49

Status of the Company's receivables from Portinho S.A.16 aug 2023 08:19

Consolidated interim report 1 January – 30 June 2023 15 aug 2023 13:54

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) receives USPTO Notice of Allowance for a method of treatment patent on its topical wound-healing composition.30 jun 2023 17:56

Status of the company's receivables from Portinho S.A. with payment deadline 1 July 2023 15 jun 2023 12:00

Changes to the Board of Directors in Pharma Equity Group 14 jun 2023 08:30

New CMO in Pharma Equity Groups subsidiary Reponex Pharmaceuticals A/S 08 jun 2023 17:00

Encouraging preliminary data from the first part of a clinical study in pouchitis 05 jun 2023 09:10

HC Andersen Capital: Pharma Equity Group – Lifescience investment company with twofold strategy 02 jun 2023 11:52

Settlement - Purchase of shares 25 maj 2023 10:31

Managers’ transactions 10 maj 2023 06:49

Consolidated interim report 1 January – 31 March 2023 10 feb 2023 14:15

Forløb af ekstraordinær generalforsamling i Blue Vision A/S ("Blue Vision"), den 10. februar 2023